Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro

Journal of Controlled Release

Volumn 137, Issue 2, 2009, Pages 130-135

  Al Abd, Ahmed M ^a   Lee, Soo Hyeon ^b   Kim, Sun Hwa ^b   Cha, Jung Ho ^a   Park, Tae Gwan ^b   Lee, Seung Jin ^c   Kuh, Hyo Jeong ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c Ewha Womans University   (South Korea)

Author keywords

Multicellular layers; Polyelectrolyte complex micelle; siRNA; Solid tumors; Vascular endothelial growth factor

Indexed keywords

MULTICELLULAR LAYERS; POLYELECTROLYTE COMPLEX MICELLE; SIRNA; SOLID TUMORS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

BIOACTIVITY; CELL CULTURE; CELLS; GENETIC ENGINEERING; MACROMOLECULES; ONCOLOGY; PEPTIDES; POLYELECTROLYTES; SELF ASSEMBLY; SUPRAMOLECULAR CHEMISTRY; TUMORS;

MICELLES;

MESSENGER RNA; POLYELECTROLYTE; SMALL INTERFERING RNA; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; EXTRAVASATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MICELLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TIME;

CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; COLORECTAL NEOPLASMS; GENE SILENCING; GENE THERAPY; HUMANS; MICELLES; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67349234877     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.03.009     Document Type: Article

References (38)

1. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 6836 (2001) 494-498
2. Leung R.K., and Whittaker P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 107 2 (2005) 222-239
3. Kang J.S., Yum Y.N., Han E., Kim J.H., Lee E.M., Ryu D.-Y., Kim Y.H., Yang S.H., Kim S.H., and Park S.N. Evaluation of potential biomarkers for thioacetamide-induced hepatotoxicity using siRNA. Biomol. Ther. 16 3 (2008) 197-202
4. Song E., Lee S.K., Wang J., Ince N., Ouyang N., Min J., Chen J., Shankar P., and Lieberman J. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9 3 (2003) 347-351
5. Karagiannis T.C., and El-Osta A. RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther. 12 10 (2005) 787-795
6. Cheng J.C., Moore T.B., and Sakamoto K.M. RNA interference and human disease. Mol. Genet. Metab. 80 1-2 (2003) 121-128
7. Ryther R.C., Flynt A.S., Phillips J.A., 3rd, and Patton J.G. siRNA therapeutics: big potential from small RNAs. Gene Ther. 12 1 (2005) 5-11
8. Layzer J.M., McCaffrey A.P., Tanner A.K., Huang Z., Kay M.A., and Sullenger B.A. In vivo activity of nuclease-resistant siRNAs. RNA 10 5 (2004) 766-771
9. Choung S., Kim Y.J., Kim S., Park H.O., and Choi Y.C. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 342 3 (2006) 919-927
10. Park T.G., Jeong J.H., and Kim S.W. Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev. 58 4 (2006) 467-486
11. Landen Jr. C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., and Sood A.K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65 15 (2005) 6910-6918
12. Pal A., Ahmad A., Khan S., Sakabe I., Zhang C., Kasid U.N., and Ahmad I. Systemic delivery of Raf siRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int. J. Oncol. 26 4 (2005) 1087-1091
13. Matsumoto G., Kushibiki T., Kinoshita Y., Lee U., Omi Y., Kubota E., and Tabata Y. Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Sci. 97 4 (2006) 313-321
14. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., and Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 64 10 (2004) 3365-3370
15. de Fougerolles A., Vornlocher H.P., Maraganore J., and Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6 6 (2007) 443-453
16. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., and Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U S A 92 16 (1995) 7297-7301
17. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 12 3 (2005) 217-227
18. Kerbel R.S. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. Cancer Res. Treat 39 4 (2007) 150-159
19. Fan F., Wey J.S., McCarty M.F., Belcheva A., Liu W., Bauer T.W., Somcio R.J., Wu Y., Hooper A., Hicklin D.J., and Ellis L.M. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24 16 (2005) 2647-2653
20. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 5 (2005) 1011-1027
21. Calvani M., Trisciuoglio D., Bergamaschi C., Shoemaker R.H., and Melillo G. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res. 68 1 (2008) 285-291
22. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., and Park T.G. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control Release 116 2 (2006) 123-129
23. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., and Park T.G. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control Release 129 2 (2008) 107-116
24. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target 15 7-8 (2007) 457-464
25. Iyer A.K., Khaled G., Fang J., and Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11 17-18 (2006) 812-818
26. Tredan O., Galmarini C.M., Patel K., and Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 99 19 (2007) 1441-1454
27. Minchinton A.I., and Tannock I.F. Drug penetration in solid tumours. Nat Rev. Cancer 6 8 (2006) 583-592
28. Fracasso G., and Colombatti M. Effect of therapeutic macromolecules in spheroids. Crit. Rev. Oncol. Hematol. 36 2-3 (2000) 159-178
29. Desoize B. Contribution of three-dimensional culture to cancer research. Crit. Rev. Oncol. Hematol. 36 2-3 (2000) 59-60
30. Hicks K.O., Pruijn F.B., Sturman J.R., Denny W.A., and Wilson W.R. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res. 63 18 (2003) 5970-5977
31. Al-Abd A.M., Lee J.H., Kim S.Y., Kun N., and Kuh H.J. Novel application of multicellular layers culture for in situ evaluation of cytotoxicity and penetration of paclitaxel. Cancer Sci. 99 2 (2008) 423-431
32. Brown L.F., Yeo K.T., Berse B., Yeo T.K., Senger D.R., Dvorak H.F., and van de Water L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176 5 (1992) 1375-1379
33. Lee M.Y., Ju W.K., Cha J.H., Son B.C., Chun M.H., Kang J.K., and Park C.K. Expression of vascular endothelial growth factor mRNA following transient forebrain ischemia in rats. Neurosci. Lett. 265 2 (1999) 107-110
34. Guan H., Zhou Z., Wang H., Jia S.F., Liu W., and Kleinerman E.S. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin. Cancer Res. 11 7 (2005) 2662-2669
35. Gautam A., Densmore C.L., Xu B., and Waldrep J.C. Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery. Mol. Ther. 2 1 (2000) 63-70
36. Lee S.H., Kim S.H., and Park T.G. Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. Biochem. Biophys. Res. Commun. 357 2 (2007) 511-516
37. Lee H., Mok H., Lee S., Oh Y.K., and Park T.G. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J. Control Release 119 2 (2007) 245-252
38. Barr M.P., Bouchier-Hayes D.J., and Harmey J.J. Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. Int. J. Oncol. 32 1 (2008) 41-48